A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC) (BIO300)

November 19, 2018
https://clinicaltrials.gov/ct2/results?id=NCT02567799
Cancer - Lung
Principal Investigator: Benjamin Movsas, MD, Ding Wang, MD
Lung Cancer, Lung, Cancer, BIO, BIO300
Accepting Participants